KRAS Mutation and Incidence of the Colorectal Carcinoma in Martinique Between 2007 and 2009

Overview

– There is no data at present concerning the KRAS mutation in patients from Martinique with colorectal cancer. Despite the fact that the incidence of this disease continues to increase there is no recent data to confirm it. This study has a descriptive purpose, allowing a comparison of the population from Martinique to other populations. – A study of incidence of colorectal cancer, overseen by the Association from Martinique for the Epidemiological Search on Cancer (AMREC), also leads to a better knowledge of the local characteristics of the colorectal cancer. – These two descriptive characteristics of colorectal cancer in Martinique will be useful data for the health professionals to provide their patients better care.

Full Title of Study: “Study of KRAS Mutation in 250 Cases of Colorectal Carcinoma and Study of the Incidence of the Disease in Martinique, From 2007 to 2009”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: October 2011

Detailed Description

– The colorectal carcinogenesis is complex. It influences among others, the EGFR (Epidermal Growth Factor Receptor) which activation leads to tumoral proliferation, differentiation and invasion. The binding of the EGF (Epidermal Growth Factor) or of another ligand to the EGFR is responsible for the activation of the Ras- Raf and Pi3k pathways. – The mutation of the genes KRAS, BRAF or PIK3CA results in their continuous activation, independently of the activation or of the pharmacological blocking of EGFR. The most frequently found mutation affects the KRAS gene (20 to 50 % of the cases). 90 % of these mutations are situated on codons 12 and 13 of this gene (70 % codon 12 and 30 % codon 13). These mutations are responsible for a decrease of the GTPase activity of the ras protein, which stays then in active conformation bound to the GTP. This leads to the blocking of the pathway and to the inactivity of the pharmacological blocking of EGFR.

Arms, Groups and Cohorts

  • Patients with colorectal carcinoma
    • Patient with colorectal carcinoma operated in Martinique between January 1st, 2007 and December 31st, 2009

Clinical Trial Outcome Measures

Primary Measures

  • Frequency of KRAS mutation
    • Time Frame: 4 months
    • Estimate the frequency of the KRAS mutation detected in paraffin embedded blocks of colorectal carcinoma operated in Martinique between 2007 and 2009

Secondary Measures

  • The incidence of the colorectal carcinoma
    • Time Frame: 4 months
    • Estimate the incidence of the colorectal carcinoma in Martinique between 2007 and 2009.

Participating in This Clinical Trial

Inclusion Criteria

  • for the study of the KRAS mutation: 250 patients drawn by lots among the cases of colorectal carcinoma diagnosed between January 1st, 2007 and December 31st, 2009 in Martinique – for the study of incidence: patient for whom was diagnosed a colorectal carcinoma between January 1st, 2007 and December 31st, 2009 – patient unopposed and in free agreement to participate in this study – patient having his main home in Martinique at the time of the diagnosis – patient 18 years old and over Exclusion Criteria:

  • patient whose diagnosis is prior to 2007 and later in 2009 – patient having shown opposition to the participation in this study – patient minor or under guardianship – patient not having his main home in Martinique at the time of the diagnosis

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University Hospital Center of Martinique
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Odile BERA, MD, Principal Investigator, Laboratoire de virologie – Centre Hospitalier Universitaire de Fort de France

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.